An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Trial Profile

An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Semaglutide (Primary) ; Atorvastatin; Digoxin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 27 Mar 2017 Results of effects of semaglutide on pharmacokinetics of concomitant medication from two phase I studies including this study published in the Clinical Pharmacokinetics
    • 12 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 04 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top